Furthermore, no studies have explored the relationship between AM-induced improvements and established serum biomarkers of NAFLD, such as fibroblast growth factor 21 (FGF21) and cytokeratin-18 (CK18), which limits the ability to quantitatively assess its intervention effects during disease progression. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatotic liver disease.